MALVERN, PA — Endo, Inc. (OTCQX: NDOI) revealed new insights from a post hoc data analysis of its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or CCH) for the treatment of Peyronie’s disease (PD). The findings were presented this week at the 89th annual meeting of the Southeastern Section of the American Urological Association (SESAUA), held from March 12 to 15, 2025.
Key Findings
The analysis examined CCH treatment outcomes related to penile curvature improvement across participants regardless of their level of pain or disease duration. Data pooled from two randomized, double-blind, placebo-controlled Phase 3 studies demonstrated that patients experiencing moderate-to-severe pain or no pain at baseline showed comparable outcomes. Results also indicated that disease duration, whether 12–18 months or over 18 months, did not significantly affect the efficacy of CCH therapy.
These findings are consistent with previous research supporting the safety and effectiveness of CCH during the acute phase of Peyronie’s disease. They also challenge the traditional “watchful waiting” approach for patients with ongoing pain, potentially broadening treatment options for those affected regardless of their pain status or disease stage.
Dr. Gregory A. Broderick, the study’s presenting author, emphasized the importance of these findings for the medical community. “I’m looking forward to sharing these medical insights to help healthcare providers reconsider how they approach the phases of Peyronie’s disease, as current literature may be limiting or delaying treatment options,” said Dr. Broderick. He further noted that the analysis “suggests that collagenase clostridium histolyticum could be a viable alternative to watchful waiting for patients regardless of their disease phase or pain status.”
Potential Impact on Patient Care
The presentation at SESAUA underscores the significance of this research in shaping future treatment approaches for Peyronie’s disease. By demonstrating that pain or prolonged disease duration are not barriers to CCH therapy, the findings could pave the way for more proactive treatment strategies, enhancing patient outcomes and quality of life.
Looking ahead, the continued exploration of XIAFLEX® and its applications signals a promising shift in the treatment paradigm for Peyronie’s disease. Endo’s research represents a critical step toward expanding therapeutic options and improving care for this condition.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.